We are live on ! Find out more

vTv Therapeutics

VTVT

Market cap $128M

32.36 USD

-0.44

1.34%

At close Updated Aug 28, 4:00 PM EDT

Pre-market

After hours

32.35

-0.01

0.03%

1 day

-1.34%

5 days

-3.17%

1 month

4.12%

3 months

-3.4%

6 months

-9.1%

Year to date

-18.28%

1 year

75.87%

5 years

-57.2%

10 years

-85.29%

About: vTv Therapeutics Inc is a late-stage biopharmaceutical company focused on developing oral, small-molecule drug candidates intended to help treat people living with diabetes and other chronic diseases. Its clinical pipeline is led by cadisegliatin (TTP399), a novel, small-molecule, liver-selective glucokinase activator (GKA) currently being evaluated as a potential oral adjunctive therapy to insulin for the treatment of type 1 diabetes (T1D). In addition, the company is also engaged in the research and development of other candidates in its pipeline through collaborations with academic partners and license agreements, which include TTP273, HPP737, TTP-RA, Mavodelpar (HPP593), HPP971, and HPP3033, being studied and developed to counter various chronic diseases.

Employees: 26

Healthcare Biotechnology

News

Positive

Neutral

Negative

Sentiment 3-Months

Positive 0%

Neutral 100%

Negative 0%

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., Aug. 19, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

Phase 3 CATT1 trial evaluating cadisegliatin for the treatment of type 1 diabetes (T1D) expected to complete enrollment in third quarter of 2026 Cadisegliatin Phase 2a hybrid closed-loop trial (Hybrid CATT1) in T1D to initiate before year end 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout Company to host Key Opinion Leader (KOL) event in the fourth quarter of 2026 highlighting cadisegliatin and its potential in people with T1D HIGH POINT, N.C., Aug. 06, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company advancing cadisegliatin, a novel oral investigational therapy for type 1 diabetes (T1D), today reported financial results for the second quarter ended June 30, 2026, and provided a corporate update.

vTv Therapeutics Reports Second Quarter 2026 Financial Results and Provides Corporate Update

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., July 28, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 23,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 12,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., June 02, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 2,500 stock options to purchase shares of common stock to a non-executive employee as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

Zacks Investment Research

vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable

If you are looking for stocks that are well positioned to maintain their recent uptrend, vTv Therapeutics (VTVT) could be a great choice. It is one of the several stocks that passed through our "Recent Price Strength" screen.

vTv Therapeutics (VTVT) is on the Move, Here's Why the Trend Could be Sustainable

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

Phase 3 CATT1 completion of enrollment on track for the third quarter of 2026 Strong balance sheet expected to fund operations through anticipated CATT1 topline data readout HIGH POINT, N.C., May 13, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today reported financial results for the first quarter ended March 31, 2026, and provided a corporate update.

vTv Therapeutics Reports First Quarter 2026 Financial Results and Provides Corporate Update

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

HIGH POINT, N.C., May 08, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that it granted 39,500 stock options to purchase shares of common stock to two non-executive employees as a material inducement to employment in accordance with Nasdaq Listing Rule 5635(c)(4).

vTv Therapeutics Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)

vTv Therapeutics to Participate in Upcoming May Investor Conferences

HIGH POINT, N.C., May 07, 2026 (GLOBE NEWSWIRE) -- vTv Therapeutics Inc. (Nasdaq: VTVT), a late-stage biopharmaceutical company focused on the development of cadisegliatin, a novel, potential first-in-class oral adjunctive therapy to insulin being investigated for the treatment of type 1 diabetes (T1D), today announced that management will participate in the following investor conferences in May: H.C.

vTv Therapeutics to Participate in Upcoming May Investor Conferences

Zacks Investment Research

Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?

The mean of analysts' price targets for vTv Therapeutics (VTVT) points to a 39.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Wall Street Analysts See a 39.9% Upside in vTv Therapeutics (VTVT): Can the Stock Really Move This High?

See News Rankings

Price charts implemented using Lightweight Charts™